This result is consistent with the view that there is a synergistic interaction between α-syn and tau in mediating neurodegeneration in PD, as α-syn may increase tau aggregation [32–34] and treating A53T mice with tau oligomer specific monoclonal antibody can alleviate PD-like pathophysiological phenotypes [35]. This evidence concerns the gene MAPT and Parkinson disease.